Table_3_Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study.DOCX
Introduction: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disease with high symptom burden, of unknown etiology, with no established treatment. We observed patients with long-standing ME/CFS who got cancer, and who reported improvement of ME/CFS symptoms after chemotherapy including cyclophosphamide, forming the basis for this prospective trial.
Materials and methods: This open-label phase II trial included 40 patients with ME/CFS diagnosed by Canadian criteria. Treatment consisted of six intravenous infusions of cyclophosphamide, 600–700 mg/m2, given at four-week intervals with follow-up for 18 months, extended to 4 years. Response was defined by self-reported improvements in symptoms by Fatigue score, supported by Short Form 36 (SF-36) scores, physical activity measures and other instruments. Repeated measures of outcome variables were assessed by General linear models. Responses were correlated with specific Human Leukocyte Antigen (HLA) alleles.
Results: The overall response rate by Fatigue score was 55.0% (22 of 40 patients). Fatigue score and other outcome variables showed significant improvements compared to baseline. The SF-36 Physical Function score increased from mean 33.0 at baseline to 51.5 at 18 months (all patients), and from mean 35.0 to 69.5 among responders. Mean steps per 24 h increased from mean 3,199 at baseline to 4,347 at 18 months (all patients), and from 3,622 to 5,589 among responders. At extended follow-up to 4 years 68% (15 of 22 responders) were still in remission. Patients positive for HLA-DQB1*03:03 and/or HLA-C*07:04 (n = 12) had significantly higher response rate compared to patients negative for these alleles (n = 28), 83 vs. 43%, respectively. Nausea and constipation were common grade 1–2 adverse events. There were one suspected unexpected serious adverse reaction (aggravated POTS) and 11 serious adverse events in eight patients.
Conclusion: Intravenous cyclophosphamide treatment was feasible for ME/CFS patients and associated with an acceptable toxicity profile. More than half of the patients responded and with prolonged follow-up, a considerable proportion of patients reported ongoing remission. Without a placebo group, clinical response data must be interpreted with caution. We nevertheless believe a future randomized trial is warranted.
Clinical Trial Registration:www.ClinicalTrials.gov, identifier: NCT02444091.
History
References
- https://doi.org//10.1177/1359105318784161
- https://doi.org//10.1371/journal.pone.0197811
- https://doi.org//10.1111/jsr.12703
- https://doi.org//10.1300/J092v11n01_02
- https://doi.org//10.1186/1741-7015-9-91
- https://doi.org//10.1371/journal.pone.0132421
- https://doi.org//10.1186/1471-2458-11-402
- https://doi.org//10.3389/fimmu.2018.00229
- https://doi.org//10.1007/s10067-018-4009-2
- https://doi.org//10.1007/s12035-013-8553-0
- https://doi.org//10.1016/j.autrev.2018.01.009
- https://doi.org//10.1073/pnas.1710519114
- https://doi.org//10.1093/intimm/dxt068
- https://doi.org//10.1371/journal.pone.0193672
- https://doi.org//10.1016/j.bbi.2015.09.013
- https://doi.org//10.1007/s12035-018-1354-8
- https://doi.org//10.1002/cncr.27612
- https://doi.org//10.1172/jci.insight.89376
- https://doi.org//10.1039/C6MB00600K
- https://doi.org//10.1038/srep34990
- https://doi.org//10.1073/pnas.1607571113
- https://doi.org//10.1038/s41598-018-28477-9
- https://doi.org//10.1186/1471-2377-11-62
- https://doi.org//10.1375/twin.10.5.729
- https://doi.org//10.1093/clinids/18.Supplement_1.S154
- https://doi.org//10.1177/039463200902200320
- https://doi.org//10.1136/jcp.2004.022681
- https://doi.org//10.1038/s41598-020-62157-x
- https://doi.org//10.3389/fonc.2018.00163
- https://doi.org//10.1371/journal.pone.0129898
- https://doi.org//10.1371/journal.pone.0026358
- https://doi.org//10.1186/1471-2377-9-28
- https://doi.org//10.7326/M18-1451
- https://doi.org//10.1038/nrclinonc.2009.146
- https://doi.org//10.1016/j.ejim.2013.02.008
- https://doi.org//10.1093/rheumatology/keh082
- https://doi.org//10.4061/2011/961702
- https://doi.org//10.1016/S0733-8635(05)70194-7
- https://doi.org//10.1007/s00280-016-3152-1
- https://doi.org//10.1001/jama.292.10.1195
- https://doi.org//10.1016/S0895-4356(98)00098-5
- https://doi.org//10.1097/00005650-199206000-00002
- https://doi.org//10.1080/14034940410028406
- https://doi.org//10.1001/archneur.1989.00520460115022
- https://doi.org//10.2522/ptj.20100291
- https://doi.org//10.1007/s00421-011-2131-9
- https://doi.org//10.1093/jnci/djj243
- https://doi.org//10.1016/j.bpobgyn.2018.06.010
- https://doi.org//10.1016/j.amjmed.2005.08.045
- https://doi.org//10.1200/JCO.2015.65.8864
- https://doi.org//10.1016/S0895-4356(98)00081-X
- https://doi.org//10.1111/cei.12696
- https://doi.org//10.1016/j.jaci.2018.11.038
- https://doi.org//10.1182/blood.V84.12.4257.bloodjournal84124257
- https://doi.org//10.2215/CJN.13071211
- https://doi.org//10.3389/fped.2019.00012
- https://doi.org//10.1097/01.psy.0000156969.76986.e0
- https://doi.org//10.1007/s40122-017-0071-8
- https://doi.org//10.1016/0268-960X(92)90028-O
- https://doi.org//10.1002/14651858.CD010908.pub2
- https://doi.org//10.1111/j.1365-3083.2009.02308.x
- https://doi.org//10.12932/AP0733
- https://doi.org//10.1186/1479-5876-11-68
- https://doi.org//10.1186/1479-5876-9-81
- https://doi.org//10.1084/jem.20040168
- https://doi.org//10.1016/j.cnp.2020.01.003
- https://doi.org//10.1086/685054
- https://doi.org//10.1007/s00421-019-04222-6
- https://doi.org//10.1001/jamaneurol.2019.2917
- https://doi.org//10.1016/j.semarthrit.2018.08.003
- https://doi.org//10.1007/s11306-015-0816-5
- https://doi.org//10.14814/phy2.14138
- https://doi.org//10.1016/j.ijcard.2011.10.030
Usage metrics
Read the peer-reviewed publication
Categories
- Radiology and Organ Imaging
- Foetal Development and Medicine
- Obstetrics and Gynaecology
- Medical Genetics (excl. Cancer Genetics)
- Medical and Health Sciences not elsewhere classified
- Dermatology
- Emergency Medicine
- Gastroenterology and Hepatology
- Geriatrics and Gerontology
- Intensive Care
- Primary Health Care
- Nephrology and Urology
- Nuclear Medicine
- Orthopaedics
- Otorhinolaryngology
- Pathology (excl. Oral Pathology)
- Family Care